Trials / Completed
CompletedNCT05022849
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-75229414 | JNJ-75229414 infusion will be administered intravenously. |
| DRUG | Bridging Therapy | Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously. |
Timeline
- Start date
- 2021-09-28
- Primary completion
- 2026-03-11
- Completion
- 2026-03-11
- First posted
- 2021-08-26
- Last updated
- 2026-04-17
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05022849. Inclusion in this directory is not an endorsement.